CoChat

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Open access
Moschos, Stergios J., Sullivan, Ryan J., Hwu, Wen-Jen, Ramanathan, Ramesh K., Adjei, Alex A., Fong, Peter C., Shapira-Frommer, Ronnie, Tawbi, Hussein A., Rubino, Joseph, Rush, Thomas S., Zhang, Da, Miselis, Nathan R., Samatar, Ahmed A., Chun, Patrick, Rubin, Eric H., Schiller, James, Long, Brian J., Dayananth, Priya, Carr, Donna, Kirschmeier, Paul, Bishop, W. Robert, Deng, Yongqi, Cooper, Alan, Shipps, Gerald W., Moreno, Blanca Homet, Robert, Lidia, Ribas, Antoni, Flaherty, Keith T. · 2018 · JCI Insight
Cited by 147

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade. The dual mechanism inhibitor SCH772984 has shown promising preclinical activity across various BRAFV600/RAS-mutant cancer cell lines and human cancer xenografts. METHODS: We have developed an orally bioavailable ERK inhibitor, MK-8353; conducted preclinical studies to demonstrate activity, pharmacodynamic endpoints, dosing, and schedule; completed a study in healthy volunteers (P07652); and subsequently performed a phase I clinical trial in patients with advanced solid tumors (MK-8353-001). In the P07652 study, MK-8353 was administered as a single dose in 10- to 400-mg dose cohorts, whereas in the MK-8353-001 study, MK-8353 was administered in 100- to 800-mg dose cohorts orally twice daily. Safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity were analyzed. RESULTS: MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models. Forty-eight patients were enrolled in the P07652 study, and twenty-six patients were enrolled in the MK-8353-001 study. Adverse events included diarrhea (44%), fatigue (40%), nausea (32%), and rash (28%). Dose-limiting toxicity was observed in the 400-mg and 800-mg dose cohorts. Sufficient exposure to MK-8353 was noted that correlated with biological activity in preclinical data. Three of fifteen patients evaluable for treatment response in the MK-8353-001 study had partial response, all with BRAFV600-mutant melanomas. CONCLUSION: MK-8353 was well tolerated up to 400 mg twice daily and exhibited antitumor activity in patients with BRAFV600-mutant melanoma. However, antitumor activity was not particularly correlated with pharmacodynamic parameters. TRIAL REGISTRATION: ClinicalTrials.gov NCT01358331. FUNDING: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., and NIH (P01 CA168585 and R35 CA197633).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.92352

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 147

Metadata

Authors
Moschos, S. J., Sullivan, R. J., Hwu, W.-J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., Kirschmeier, P., Bishop, W. R., Deng, Y., Cooper, A., Shipps, G. W., Moreno, B. H., Robert, L., Ribas, A., & Flaherty, K. T.
Venue
JCI Insight
Published
2018-02-22
Volume
3
Issue
4
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2788978455
Cited by
147
References
5
FWCI
5.49
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. https://app.cochat.ai/papers/10.1172/jci.insight.92352
The paper
Moschos, S. J., Sullivan, R. J., Hwu, W.-J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., . . . Flaherty, K. T. (2018). Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. https://doi.org/10.1172/jci.insight.92352

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.